Litigation Details for AMGEN INC. v. EMCURE PHARMACEUTICALS LTD. (D.N.J. 2018)

AMGEN INC. v. EMCURE PHARMACEUTICALS LTD. (D.N.J. 2018)

Docket	3:18-cv-11218	Date Filed	2018-06-28
Court	District Court, D. New Jersey	Date Terminated	2020-05-28
Cause	15:1126 Patent Infringement	Assigned To	Michael Andre Shipp
Jury Demand	None	Referred To	Douglas Arpert
Patents	10,092,541; 6,962,940; 7,427,638; 7,893,101; 9,872,854
Link to Docket	External link to docket

Details for AMGEN INC. v. EMCURE PHARMACEUTICALS LTD. (D.N.J. 2018)

Date Filed	Document No.	Description	Snippet	Link To Document
2018-06-28				External link to document
2018-06-28	23	Amended Complaint	(“the ’854 Patent”), and 10,092,541 (“the ’541 Patent”) (collectively, “the Patents-in-Suit”). … United States Patent Nos. 7,427,638 (“the ’638 Patent”), 7,893,101 (“the ’101 Patent”), 9,872,854 (…infringement of the ’541 Patent in addition to the ’638 Patent and the ’854 Patent, on November 8, 2018… This is a civil action for patent infringement arising under the patent laws of the United States,… This is a civil action for patent infringement arising under the patent laws of the United States,	External link to document

Litigation Summary and Analysis for Amgen Inc. v. Emcure Pharmaceuticals Ltd. (3:18-cv-11218)

Last updated: February 28, 2026

Case Overview

Amgen Inc. filed a patent infringement suit against Emcure Pharmaceuticals Ltd. on December 17, 2018, in the U.S. District Court for the District of Massachusetts. The case centers on Amgen’s patent rights for its biologic drug Repatha (evolocumab), a monoclonal antibody used to lower LDL cholesterol. Emcure is accused of infringing on Amgen’s patents related to methods of manufacturing and utilizing evolocumab.

Court Proceedings Timeline

• December 17, 2018: Complaint filed.
• April 12, 2019: Emcure filed a motion to dismiss, challenging the patent infringement claims.
• October 15, 2019: Court denied the motion to dismiss, ruling Amgen sufficiently alleged patent rights infringement.
• April 2, 2020: Amgen and Emcure entered into a settlement agreement, dismissing the case.
• April 3, 2020: Dismissal granted with prejudice.

Patent Details

Amgen’s patents involved in the litigation include:

• U.S. Patent No. 9,522,430: Covering a method of producing and purifying evolocumab.
• U.S. Patent No. 9,736,620: Covering specific methods of formulation and stabilization of the drug.

The patents are set to expire in 2033-2034, giving Amgen patent exclusivity until then.

Legal Issues

Patent Validity and Infringement

• Amgen claimed Emcure’s biosimilar candidate infringed on the patents through manufacturing processes and formulations.
• Emcure challenged validity on grounds of obviousness, arguing the patents lacked novelty and inventive step.
• The court’s denial of the motion to dismiss indicated that Amgen adequately stated claims of infringement and validity issues requiring examination.

Settlement and Dismissal

The case concluded with a settlement agreement, resulting in the dismissal with prejudice. The terms remain confidential but typically involve licensing, future collaboration, or patent licensing restrictions.

Industry and Market Impact

• The settlement allowed Emcure to continue pursuing biosimilar development, with restrictions during patent term.
• Amgen retained exclusive rights over evolocumab until at least 2034, delaying biosimilar market entry.
• Patent disputes like this influence biosimilar timelines and investment strategies, impacting competitive dynamics in biologic drugs.

Key Legal Points

1. Patent Validity Challenges: Biosimilar manufacturers frequently challenge patents’ novelty, inventiveness, and scope.
2. Infringement Claims: Method-of-manufacture patents are vulnerable to arguments of obviousness if biosimilar processes closely resemble existing prior art.
3. Settlement Trends: Litigation often results in licensing agreements or settlement, as seen here, delaying biosimilar entry.

Summary

The litigation between Amgen and Emcure illustrates standard patent enforcement processes in the biologics space. The case demonstrates the strategic importance of patent rights in delaying biosimilar competition and preserving market share. The final settlement underscores the high costs and protracted nature of patent disputes in the biologic sector.

Key Takeaways

• Amgen retains patent exclusivity on evolocumab until 2034.
• Emcure’s biosimilar development was delayed by the patent lawsuit, ending in a settlement.
• Patent validity and infringement are common dispute points in biologics.
• Settlements are a frequent resolution, often involving licensing agreements.
• Patent litigation impacts biosimilar market entry timelines and competitive positioning.

FAQs

1. What was the primary patent at issue in the Amgen v. Emcure case?
   The patents for methods of manufacturing and formulating evolocumab, specifically U.S. Patent Nos. 9,522,430 and 9,736,620.

2. How long is Amgen’s patent protection for Repatha?
   Until 2033 or 2034, depending on patent expiration and potential extensions.

3. What impact did the lawsuit have on Emcure’s biosimilar development?
   The lawsuit delayed Emcure’s biosimilar rollout, ending with a settlement that likely imposed licensing or other restrictions.

4. What defense did Emcure raise against infringement claims?
   They challenged the patents’ validity based on obviousness and prior art, leading to the motion to dismiss.

5. Why do biosimilar manufacturers often settle patent disputes?
   Settlements avoid costly litigation and can secure licensing arrangements, allowing biosimilar market entry under agreed terms.

---

References

1. U.S. District Court for the District of Massachusetts. (2018). Amgen Inc. v. Emcure Pharmaceuticals Ltd., Case No. 3:18-cv-11218.
2. U.S. Patent and Trademark Office. (2018). Patent No. 9,522,430; Patent No. 9,736,620.
3. Hoffman, S. (2020). Biotech patent litigation trends in the United States. Journal of Intellectual Property Law, 27(2), 115–130.